MANIFEST-2 compares pelabresib plus ruxolitinib with placebo plus ruxolitinib for JAK-inhibitor-naive disease.
Heme Today
Heme Today covers the latest news and analyses in bleeding, clotting, red blood cell, and iron disorders for hematologists and oncologists focused on bleeding disorders.
Advertisement
Latest News
In a phase 3 study, patients who received recombinant ADAMTS13 did not experience acute TTP events during prophylaxis.
Iron deficiency anemia was associated with 39% increased odds of stroke, independent of the risk factors for stroke.
While cytoreductive drugs did not reduce thrombosis risk, interferon significantly improved myelofibrosis-free survival.
A preclinical mouse study showed hemostasis restoration, as well as use for active bleeding and internal bleeding prevention.
A novel complement-targeting agent shows impressive efficacy and safety without immunosuppression of the classical pathway.
Investigation of a HUNT Study cohort found elevated plasma MBL levels to be associated with increased risk for future VTE.
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A cohort study of extended-phase anticoagulation following acute management was performed in the phase III EINSTEIN Jr trial.
Fidanacogene elaparvovec gene therapy is a safe and effective treatment for patients with hemophilia B, research shows.
The agent targets abnormal gene expression in order to control the excessive cell proliferation that occurs in PV.
Advertisement
Conference Coverage
Major highlights with a focus on MDS from the 66th American Society of Hematology Annual Meeting & Exposition
Heme Today reports from the EHA 2024 Hybrid Congress the latest findings in hematology research and management.
Our editors are covering data on transplantation and cellular therapies from the 2024 Tandem Meetings of ASTCT® and ...
Highlighting the latest news and experts in pediatric hematology and oncology from the 2024 ASPHO Conference in Seattle.
Expert Interviews on Hematology
Blood Cancer Awareness
A phase II trial calculated a 4-year event-free survival rate of 96% and overall survival rate of 100% from the combination.
Differences were identified between patient racial groups and by urban versus rural populations.
A magnetic resonance imaging study has compared tissue iron levels and biventricular function between the two conditions.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.